(KYMR) Kymera Therapeutics - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5015751044
IRAK4, STAT6, TYK2, Protein Degradation
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 51.8% |
| Value at Risk 5%th | 77.5% |
| Relative Tail Risk | -9.15% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.81 |
| Alpha | 21.66 |
| CAGR/Max DD | 0.43 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.644 |
| Beta | 1.601 |
| Beta Downside | 1.310 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.69% |
| Mean DD | 23.47% |
| Median DD | 19.23% |
Description: KYMR Kymera Therapeutics November 08, 2025
Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biotech that designs small-molecule degraders-often called PROTACs-to harness the body’s ubiquitin-proteasome system and eliminate disease-causing proteins.
The company’s lead pipeline centers on an IRAK4 inhibitor currently in a Phase II trial for hidradenitis suppurativa and atopic dermatitis, with a second STAT6-targeted candidate for type 2 inflammatory disorders and a TYK2 program aimed at broader autoimmune indications.
Kymera has a strategic alliance with Sanofi that provides an upfront payment of roughly $50 million and up to $300 million in milestone potential for non-oncology IRAK4 programs, giving the firm a non-dilutive cash infusion and validation of its degrader platform.
As of the latest 10-Q, Kymera reported cash and equivalents of about $200 million, supporting roughly 18 months of runway at its current burn rate of $70 million per year; the biotech sector’s R&D spend is growing at a 9 % CAGR, while the global targeted protein degradation market is projected to expand at ~14 % CAGR through 2030, underscoring a favorable macro backdrop for Kymera’s technology.
For a deeper quantitative view, the ValueRay platform offers a granular breakdown of KYMR’s valuation metrics and comparable peer analysis.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-295.1m TTM) > 0 and > 6% of Revenue (6% = 2.62m TTM) |
| FCFTA -0.21 (>2.0%) and ΔFCFTA -6.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1044 % (prev 573.5%; Δ 470.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.21 (>3.0%) and CFO -227.9m > Net Income -295.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (87.3m) change vs 12m ago 14.68% (target <= -2.0% for YES) |
| Gross Margin -83.38% (prev 92.85%; Δ -176.2pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.09% (prev 8.46%; Δ -4.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -875.0 (EBITDA TTM -285.9m / Interest Expense TTM 337.0k) >= 6 (WARN >= 3) |
Altman Z'' -8.62
| (A) 0.41 = (Total Current Assets 528.3m - Total Current Liabilities 71.6m) / Total Assets 1.10b |
| (B) -0.89 = Retained Earnings (Balance) -979.0m / Total Assets 1.10b |
| (C) -0.28 = EBIT TTM -294.9m / Avg Total Assets 1.07b |
| (D) -6.27 = Book Value of Equity -977.5m / Total Liabilities 155.8m |
| Total Rating: -8.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.14
| 1. Piotroski 0.0pt |
| 2. FCF Yield -5.16% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.09 |
| 5. Debt/Ebitda 0.10 |
| 6. ROIC - WACC (= -38.04)% |
| 7. RoE -33.35% |
| 8. Rev. Trend -22.18% |
| 9. EPS Trend -32.11% |
What is the price of KYMR shares?
As of December 01, 2025, the stock is trading at USD 67.88 with a total of 450,021 shares traded.
Over the past week, the price has changed by +3.49%, over one month by +9.77%, over three months by +66.82% and over the past year by +42.19%.
Over the past week, the price has changed by +3.49%, over one month by +9.77%, over three months by +66.82% and over the past year by +42.19%.
Is KYMR a buy, sell or hold?
Kymera Therapeutics has received a consensus analysts rating of 4.55.
Therefore, it is recommended to buy KYMR.
- Strong Buy: 14
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KYMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.6 | 14.3% |
| Analysts Target Price | 77.6 | 14.3% |
| ValueRay Target Price | 69.1 | 1.8% |
KYMR Fundamental Data Overview November 29, 2025
Market Cap USD = 4.88b (4.88b USD * 1.0 USD.USD)
P/S = 111.6374
P/B = 5.162
Beta = 2.296
Revenue TTM = 43.7m USD
EBIT TTM = -294.9m USD
EBITDA TTM = -285.9m USD
Long Term Debt = 84.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 84.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.46b USD (4.88b + Debt 84.0m - CCE 505.7m)
Interest Coverage Ratio = -875.0 (Ebit TTM -294.9m / Interest Expense TTM 337.0k)
FCF Yield = -5.16% (FCF TTM -230.2m / Enterprise Value 4.46b)
FCF Margin = -526.4% (FCF TTM -230.2m / Revenue TTM 43.7m)
Net Margin = -674.8% (Net Income TTM -295.1m / Revenue TTM 43.7m)
Gross Margin = -83.38% ((Revenue TTM 43.7m - Cost of Revenue TTM 80.2m) / Revenue TTM)
Gross Margin QoQ = -2581 % (prev 81.84%)
Tobins Q-Ratio = 4.05 (Enterprise Value 4.46b / Total Assets 1.10b)
Interest Expense / Debt = 0.12% (Interest Expense 98.0k / Debt 84.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -233.0m (EBIT -294.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 528.3m / Total Current Liabilities 71.6m)
Debt / Equity = 0.09 (Debt 84.0m / totalStockholderEquity, last quarter 946.3m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -29.0m / EBITDA -285.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -230.2m)
Total Stockholder Equity = 884.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.78% (Net Income -295.1m / Total Assets 1.10b)
RoE = -33.35% (Net Income TTM -295.1m / Total Stockholder Equity 884.9m)
RoCE = -30.43% (EBIT -294.9m / Capital Employed (Equity 884.9m + L.T.Debt 84.0m))
RoIC = -26.33% (negative operating profit) (NOPAT -233.0m / Invested Capital 884.9m)
WACC = 11.71% (E(4.88b)/V(4.97b) * Re(11.91%) + D(84.0m)/V(4.97b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 11.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.14%
Fair Price DCF = unknown (Cash Flow -230.2m)
EPS Correlation: -32.11 | EPS CAGR: -32.28% | SUE: -0.55 | # QB: 0
Revenue Correlation: -22.18 | Revenue CAGR: -36.61% | SUE: -1.95 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.98 | Chg30d=+0.103 | Revisions Net=+6 | Analysts=10
EPS current Year (2025-12-31): EPS=-3.48 | Chg30d=-0.053 | Revisions Net=+0 | Growth EPS=-16.7% | Growth Revenue=+13.4%
EPS next Year (2026-12-31): EPS=-3.82 | Chg30d=+0.216 | Revisions Net=+5 | Growth EPS=-10.0% | Growth Revenue=-11.2%
P/S = 111.6374
P/B = 5.162
Beta = 2.296
Revenue TTM = 43.7m USD
EBIT TTM = -294.9m USD
EBITDA TTM = -285.9m USD
Long Term Debt = 84.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 84.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.46b USD (4.88b + Debt 84.0m - CCE 505.7m)
Interest Coverage Ratio = -875.0 (Ebit TTM -294.9m / Interest Expense TTM 337.0k)
FCF Yield = -5.16% (FCF TTM -230.2m / Enterprise Value 4.46b)
FCF Margin = -526.4% (FCF TTM -230.2m / Revenue TTM 43.7m)
Net Margin = -674.8% (Net Income TTM -295.1m / Revenue TTM 43.7m)
Gross Margin = -83.38% ((Revenue TTM 43.7m - Cost of Revenue TTM 80.2m) / Revenue TTM)
Gross Margin QoQ = -2581 % (prev 81.84%)
Tobins Q-Ratio = 4.05 (Enterprise Value 4.46b / Total Assets 1.10b)
Interest Expense / Debt = 0.12% (Interest Expense 98.0k / Debt 84.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -233.0m (EBIT -294.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 528.3m / Total Current Liabilities 71.6m)
Debt / Equity = 0.09 (Debt 84.0m / totalStockholderEquity, last quarter 946.3m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -29.0m / EBITDA -285.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -230.2m)
Total Stockholder Equity = 884.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.78% (Net Income -295.1m / Total Assets 1.10b)
RoE = -33.35% (Net Income TTM -295.1m / Total Stockholder Equity 884.9m)
RoCE = -30.43% (EBIT -294.9m / Capital Employed (Equity 884.9m + L.T.Debt 84.0m))
RoIC = -26.33% (negative operating profit) (NOPAT -233.0m / Invested Capital 884.9m)
WACC = 11.71% (E(4.88b)/V(4.97b) * Re(11.91%) + D(84.0m)/V(4.97b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 11.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.14%
Fair Price DCF = unknown (Cash Flow -230.2m)
EPS Correlation: -32.11 | EPS CAGR: -32.28% | SUE: -0.55 | # QB: 0
Revenue Correlation: -22.18 | Revenue CAGR: -36.61% | SUE: -1.95 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.98 | Chg30d=+0.103 | Revisions Net=+6 | Analysts=10
EPS current Year (2025-12-31): EPS=-3.48 | Chg30d=-0.053 | Revisions Net=+0 | Growth EPS=-16.7% | Growth Revenue=+13.4%
EPS next Year (2026-12-31): EPS=-3.82 | Chg30d=+0.216 | Revisions Net=+5 | Growth EPS=-10.0% | Growth Revenue=-11.2%
Additional Sources for KYMR Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle